Avid Radiopharmaceuticals
As of the edition of 20 October 2026, Avid Radiopharmaceuticals runs 4 drugs, 2 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Avid Radiopharmaceuticals was acquired in 2010; successor DISTA PRODUCTS CO DIV ELI LILLY AND CO.
- Avid Radiopharmaceuticals: acquired in 2010; successor DISTA PRODUCTS CO DIV ELI LILLY AND CO
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Stopped | 2 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Florbetapir | Ends 2027 (patent) | 0 |
| Flortaucipir | Ends 2032 (patent) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| MAPT Microtubule-associated protein tau | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Avid Radiopharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 46 trials led
- Mental health: 43 trials led
- Nutrition and metabolism: 4 trials led